ATE243530T1 - Virus impfstoff - Google Patents

Virus impfstoff

Info

Publication number: ATE243530T1
Authority: AT; Austria
Prior art keywords: virus; strains; inactivated; neuraminidase; hemagglutinin
Prior art date: 1995-04-28

Application number

AT96913234T

Other languages

English (en)

Inventor

Gale Eugene Smith

James T Mattews

Edwin D Kilbourne

Bert E Johannson

Bethanie E Wilkinson

Andrei I Voznesensky

Craig S Hackett

Franklin Volvovitz

Original Assignee

Protein Sciences Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-04-28

Filing date

1996-04-26

Publication date

2003-07-15

1996-04-26 Application filed by Protein Sciences Corp filed Critical Protein Sciences Corp

2003-07-15 Application granted granted Critical

2003-07-15 Publication of ATE243530T1 publication Critical patent/ATE243530T1/de

Links

241000700605 Viruses Species 0.000 title abstract 11
229960005486 vaccine Drugs 0.000 title abstract 3
108010006232 Neuraminidase Proteins 0.000 abstract 3
102000005348 Neuraminidase Human genes 0.000 abstract 3
239000000185 hemagglutinin Substances 0.000 abstract 3
101710091045 Envelope protein Proteins 0.000 abstract 2
101710154606 Hemagglutinin Proteins 0.000 abstract 2
101710093908 Outer capsid protein VP4 Proteins 0.000 abstract 2
101710135467 Outer capsid protein sigma-1 Proteins 0.000 abstract 2
101710176177 Protein A56 Proteins 0.000 abstract 2
101710188315 Protein X Proteins 0.000 abstract 2
102100021696 Syncytin-1 Human genes 0.000 abstract 2
230000002163 immunogen Effects 0.000 abstract 2
229960003971 influenza vaccine Drugs 0.000 abstract 2
102000007644 Colony-Stimulating Factors Human genes 0.000 abstract 1
108010071942 Colony-Stimulating Factors Proteins 0.000 abstract 1
102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 abstract 1
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 abstract 1
241000700588 Human alphaherpesvirus 1 Species 0.000 abstract 1
241000701074 Human alphaherpesvirus 2 Species 0.000 abstract 1
241000701044 Human gammaherpesvirus 4 Species 0.000 abstract 1
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 abstract 1
241000712079 Measles morbillivirus Species 0.000 abstract 1
208000002606 Paramyxoviridae Infections Diseases 0.000 abstract 1
241000725643 Respiratory syncytial virus Species 0.000 abstract 1
239000002671 adjuvant Substances 0.000 abstract 1
239000000427 antigen Substances 0.000 abstract 1
102000036639 antigens Human genes 0.000 abstract 1
108091007433 antigens Proteins 0.000 abstract 1
239000012634 fragment Substances 0.000 abstract 1
239000002243 precursor Substances 0.000 abstract 1
102000004169 proteins and genes Human genes 0.000 abstract 1
108090000623 proteins and genes Proteins 0.000 abstract 1
241000712461 unidentified influenza virus Species 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
- A61K39/165—Mumps or measles virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
- A61K39/25—Varicella-zoster virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
- C12N2710/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Virology (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Mycology (AREA)
Immunology (AREA)
Microbiology (AREA)
Pulmonology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

AT96913234T 1995-04-28 1996-04-26 Virus impfstoff ATE243530T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/430,971 US5976552A (en)	1995-04-28	1995-04-28	Virus vaccines
PCT/US1996/005904 WO1996033738A1 (en)	1995-04-28	1996-04-26	Improved virus vaccines

Publications (1)

Publication Number	Publication Date
ATE243530T1 true ATE243530T1 (de)	2003-07-15

Family

ID=23709884

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT96913234T ATE243530T1 (de)	1995-04-28	1996-04-26	Virus impfstoff

Country Status (11)

Country	Link
US (2)	US5976552A (de)
EP (1)	EP0830141B1 (de)
CN (1)	CN1141977C (de)
AT (1)	ATE243530T1 (de)
AU (1)	AU696690B2 (de)
CA (1)	CA2222283C (de)
DE (1)	DE69628834T2 (de)
DK (1)	DK0830141T3 (de)
ES (1)	ES2201184T3 (de)
PT (1)	PT830141E (de)
WO (1)	WO1996033738A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6485729B1 (en) *	1993-09-13	2002-11-26	Protein Sciences Corporation	Neuraminidase-supplemented compositions
US6495185B1 (en) *	1996-10-31	2002-12-17	Slk Foundation	Flavoring composition, production and use thereof
WO1998046262A1 (en) *	1997-04-16	1998-10-22	Connaught Laboratories, Inc.	Anti-influenza compositions supplemented with neuraminidase
MXPA01006214A (es) *	1998-12-17	2004-09-06	Aventis Pasteur	Composicion inmunogenica multivalente que contiene una preparacion de virus de influenza y una composicion de subunidad del virus sincicial respiratorio.
AT407958B (de) *	1999-02-11	2001-07-25	Immuno Ag	Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation
PL355287A1 (en) *	1999-09-24	2004-04-05	Smithkline Beecham Biologicals S.A.	Intranasal influenza virus vaccine
US7122018B2 (en)	2000-12-26	2006-10-17	Sensormedics Corporation	Device and method for treatment of wounds with nitric oxide
WO2004022593A2 (en) *	2002-09-09	2004-03-18	Nautilus Biotech	Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
WO2004035086A2 (en)	2002-10-16	2004-04-29	Hunter Samuel F	Method for treatment of demyelinating central nervous system disease using gm-csf
WO2004066961A2 (en) *	2003-01-20	2004-08-12	St. Jude Children's Research Hospital	Use of sendai virus as a human parainfluenza vaccine
US7282353B2 (en) *	2003-08-19	2007-10-16	Academia Sinica	Protein isolation
AR052195A1 (es)	2005-01-19	2007-03-07	Vaxinnate Corp	Composiciones de patrones moleculares asociados a patogenos en metodos de uso
GB0504436D0 (en) *	2005-03-03	2005-04-06	Glaxosmithkline Biolog Sa	Vaccine
US11865172B2 (en)	2005-04-21	2024-01-09	University Of Florida Research Foundation, Inc.	Materials and methods for respiratory disease control in canines
KR20080052512A (ko) *	2005-05-23	2008-06-11	박신, 인크.	아데노바이러스-무함유 재조합 아데노바이러스 벡터의 급속생산
WO2007057763A2 (en) *	2005-11-18	2007-05-24	Pulmonox Technologies Corporation	Nitric oxide as an anti-viral agent, vaccine and vaccine adjuvant
TWI477602B (zh)	2006-02-09	2015-03-21	Educational Foundation Jichi Medical Univ	Novel viral vector
US9333249B2 (en)	2006-02-09	2016-05-10	Educational Foundation Jichi Medical University	Recombinant baculovirus vaccine
ES2555544T3 (es)	2006-03-07	2016-01-04	Vaxinnate Corporation	Composiciones que incluyen hemaglutinina, métodos de preparación y métodos de uso de las mismas
WO2008112218A2 (en)	2007-03-12	2008-09-18	Antigen Express, Inc.	Li-rnai involved li suppression in cancer immunotherapy
CN101307310B (zh) *	2007-05-15	2012-08-08	康泰生医科技股份有限公司	具有提高产率及免疫原性的重组蛋白质表达系统
EP2014279A1 (de) *	2007-06-22	2009-01-14	Pevion Biotech AG	Virosomen enthaltend Haemagglutinin, das von über Zelllinien hergestellten Influenza-Viren stammt, Zusammensetzungen, Herstellungsverfahren, Verwendung davon
SG190562A1 (en)	2008-04-18	2013-06-28	Vaxinnate Corp	Deletion mutants of flagellin and methods of use
WO2010144797A2 (en)	2009-06-12	2010-12-16	Vaccine Technologies, Incorporated	Influenza vaccines with enhanced immunogenicity and uses thereof
US20130095130A1 (en) *	2010-01-06	2013-04-18	Vaxinnate Corporation	Methods and Compositions for Providing Protective Immunity in the Elderly
CN114010776A (zh)	2010-06-09	2022-02-08	疫苗技术股份有限公司	用于增强抗逆转录病毒治疗的hiv感染者的治疗性免疫
CA2826234A1 (en) *	2010-11-02	2012-05-10	Hector Manuel Zepeda Lopez	Novel vaccines against the a/h1n1 pandemic flu virus
DK3205353T3 (da)	2011-03-21	2021-04-06	Altimmune Inc	Hurtig- og langtidsvirkende immunologisk terapeutisk middel
US8932598B2 (en)	2012-08-28	2015-01-13	Vaxinnate Corporation	Fusion proteins and methods of use
US10022436B2 (en)	2016-01-11	2018-07-17	Verndari, Inc.	Microneedle compositions and methods of using same
CN105854009A (zh) *	2016-05-03	2016-08-17	重庆三杰众鑫生物工程有限公司	应用番鸭肝炎病毒制备灭活疫苗的制备方法
MX2023012554A (es)	2018-12-12	2023-11-08	Cambridge Tech Llc	Vacuna universal contra la gripe.
MX2024005482A (es)	2021-11-05	2024-05-22	Sanofi Sa	Vacunas hibridas multivalentes antigripales que comprenden hemaglutinina y neuraminidasa y metodos de uso de las mismas.
WO2023081798A1 (en)	2021-11-05	2023-05-11	Sanofi Pasteur Inc.	Multivalent influenza vaccines comprising recombinant hemagglutinin and neuraminidase and methods of using the same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2667245B1 (fr) *	1990-10-01	1992-11-06	Rhone Merieux	Association vaccinale contre les pathogenes infectieux.
MX9304089A (es) *	1992-07-08	1994-01-31	Schering Corp	Uso de gm-csf como una vacuna adyuvante.

1995
- 1995-04-28 US US08/430,971 patent/US5976552A/en not_active Expired - Lifetime
1996
- 1996-04-26 PT PT96913234T patent/PT830141E/pt unknown
- 1996-04-26 AU AU56312/96A patent/AU696690B2/en not_active Revoked
- 1996-04-26 CN CNB961950706A patent/CN1141977C/zh not_active Expired - Fee Related
- 1996-04-26 EP EP96913234A patent/EP0830141B1/de not_active Expired - Lifetime
- 1996-04-26 DE DE69628834T patent/DE69628834T2/de not_active Expired - Lifetime
- 1996-04-26 WO PCT/US1996/005904 patent/WO1996033738A1/en not_active Ceased
- 1996-04-26 CA CA2222283A patent/CA2222283C/en not_active Expired - Fee Related
- 1996-04-26 DK DK96913234T patent/DK0830141T3/da active
- 1996-04-26 ES ES96913234T patent/ES2201184T3/es not_active Expired - Lifetime
- 1996-04-26 AT AT96913234T patent/ATE243530T1/de active
1999
- 1999-01-22 US US09/235,901 patent/US20020071848A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20020071848A1 (en)	2002-06-13
CN1189103A (zh)	1998-07-29
CA2222283C (en)	2015-02-03
EP0830141A1 (de)	1998-03-25
WO1996033738A1 (en)	1996-10-31
DE69628834D1 (de)	2003-07-31
DK0830141T3 (da)	2003-10-20
EP0830141B1 (de)	2003-06-25
US5976552A (en)	1999-11-02
AU696690B2 (en)	1998-09-17
CN1141977C (zh)	2004-03-17
PT830141E (pt)	2003-11-28
CA2222283A1 (en)	1996-10-31
HK1013595A1 (en)	1999-09-03
DE69628834T2 (de)	2004-05-06
ES2201184T3 (es)	2004-03-16
AU5631296A (en)	1996-11-18

Legal Events

Date

Code

Title

Description

2004-02-15

UEP

Publication of translation of european patent specification

Ref document number: 0830141

Country of ref document: EP

Publication	Publication Date	Title
DE69628834D1 (de)	2003-07-31	Virus impfstoff
Hashigucci et al.	1996	Antibody responses in volunteers induced by nasal influenza vaccine combined with Escherichia coli heat-labile enterotoxin B subunit containing a trace amount of the holotoxin
EP0705109B2 (de)	2004-01-02	Adjuvantien für impfstoffe gegen das respiratorische synzitialvirus
AU2684792A (en)	1993-05-21	Porcine reproductive respiratory syndrome vaccine and diagnostic
FI102616B1 (fi)	1999-01-15	Menetelmä rokotteen valmistamiseksi ihmisen parainfluenssa-viruksen tyyppiä 3 varten ja menetelmässä käytettävä ilmentämisjärjestelmä
Kodihalli et al.	1994	A type-specific avian influenza virus subunit vaccine for turkeys: induction of protective immunity to challenge infection
RU2000116260A (ru)	2002-06-27	Вакцины с адъювантом ltb
ATE295895T1 (de)	2005-06-15	Genetischer impfstoff gegen den immunschwäche virus
MX9802285A (es)	1998-11-29	Vacunas y glicoproteinas de virus de parainfluenza.
EA200900784A1 (ru)	2009-12-30	Вакцины, включающие антиген из четырех штаммов вируса гриппа
CA2181832A1 (en)	1995-08-03	Immunization by inoculation of dna transcription unit
EA200000528A1 (ru)	2001-02-26	Способ получения вакцин для предупреждения патогенных эффектов, связанных с ретровирусной инфекцией
ATE101200T1 (de)	1994-02-15	Impfstoffe gegen menschliche respiratorische viren.
AU3887695A (en)	1996-05-02	Interleukin-12 as an adjuvant for paramyxoviridae vaccines
ATE221786T1 (de)	2002-08-15	Synthetischer impfstoff zum schutz gegen infektionen mit dem menschlichen immunschwächevirus
Downie	1970	Neuraminidase-and hemagglutinin-inhibiting antibodies in serum and nasal secretions of volunteers immunized with attenuated and inactivated influenza B/Eng/13/65 virus vaccines
ES8800358A1 (es)	1987-11-01	Un procedimiento para preparar un polipeptido hibrido.
IE32140B1 (en)	1973-04-18	Vaccines
DE69720024D1 (de)	2003-04-24	Immunisierungsverfahren in zwei schritten gegen pyramyxoviridae-viren unter verwendung abgeschwächter viraler stämme und preparation von proteinuntereinheiten
Liashenko et al.	1999	Measles IgA in the nasal washings of adult volunteers and children immunized intranasally with measles vaccine L-16
BR9909076A (pt)	2000-12-05	Vìrus atenuado do sarampo, recombinantemente gerado, isolado, vìrus do sarampo, vìrus sincicial respiratório humano (rsv), subgrupo b, atenuado, recombinantemente gerado, isolado, o rsv, subgrupo b, vacina processo para imunização de um indivìduo para induzir proteção contra vìrus do sarampo, processo para imunização de um indivìduo para induzir proteção contra o rsv, subgrupo b, composição, processo para produção de vìrus do sarampo infeccioso atenuado, processo para produção de rsv infeccioso atenuado subgrupo b
PT100460A (pt)	1993-08-31	Partiiculas derivadas de virus de herpes e vacinas que as contem
Trudel et al.	1990	Efficient intranasal vaccination of mice against human respiratory syncytial virus with an experimental iscoms subunit vaccine
Smith et al.	1988	In vitro studies on suppression of the immune response to influenza virus surface proteins
IE45441L (en)	1977-12-18	Influenza virus vaccine.